The Epilepsy Foundation of America (EFA) is calling on people across the country to go "All In" this November for National Epilepsy Awareness Month (NEAM), an annual campaign dedicated to inspiring ...

Good day, ladies and gentlemen, and welcome to LivaNova plc Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I'd now like to ...

Salesman Dagobert Renouf acted as an advertisement on his wedding day by wearing a tuxedo covered in 26 tech startup logos ...

Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete – Phase 3 X-NOVA2 and X-NOVA3 studies in ...

After market close on November 25, 2025, NetApp will announce financial results for the second quarter of fiscal year 2026, which ended October 24, 2025. NetApp executive management will host a ...

A post, shared on Reddit, features a man discussing the phenomenon of “divine possession” through a scientific perspective.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need ...

Emerging evidence implicates immune dysregulation and neuroinflammation in the pathogenesis of epilepsy, yet the causal mechanisms remain unclear.

Military veterans who develop epilepsy after a traumatic brain injury may have a higher mortality rate in the following years than veterans who develop epilepsy with no previous traumatic brain injury ...

The epilepsy clinical trials report outlines global trial scenarios, identifying opportunities in key regions and associating trends with trial phases, status, and sponsors. It aids strategic planning ...

Planned U.S. launch of Anaphylm™ in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the ...

According to DataM Intelligence, the Self-Sovereign Identity (SSI) Market Size is growing from USD 1.30 billion in 2024 to USD 44.98 billion by 2032, registering an extraordinary CAGR of 84.5% during ...